Genmab A/S (NASDAQ:GMAB) Reaches New 52-Week Low – Should You Sell?

Genmab A/S (NASDAQ:GMAB)’s stock price hit a new 52-week low during trading on Tuesday . The stock traded as low as $22.39 and last traded at $22.41, with a volume of 44298 shares trading hands. The stock had previously closed at $22.78.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on GMAB shares. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Genmab A/S in a research note on Tuesday, August 20th. BTIG Research increased their target price on Genmab A/S from $46.00 to $47.00 and gave the company a “buy” rating in a research report on Thursday, June 27th. HC Wainwright restated a “buy” rating and set a $50.00 price target on shares of Genmab A/S in a report on Wednesday, October 16th. Truist Financial lowered their price objective on Genmab A/S from $53.00 to $50.00 and set a “buy” rating for the company in a research note on Monday, September 9th. Finally, Royal Bank of Canada upgraded shares of Genmab A/S from a “sector perform” rating to an “outperform” rating in a research report on Monday, July 15th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $45.20.

Genmab A/S Trading Down 0.2 %

The business’s 50-day simple moving average is $25.50 and its two-hundred day simple moving average is $26.93. The firm has a market cap of $15.03 billion, a price-to-earnings ratio of 18.94, a P/E/G ratio of 0.71 and a beta of 0.98.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings data on Thursday, August 8th. The company reported $0.22 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.07). Genmab A/S had a net margin of 29.06% and a return on equity of 17.48%. The business had revenue of $779.50 million during the quarter, compared to analyst estimates of $734.60 million. On average, analysts forecast that Genmab A/S will post 1.27 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of GMAB. GAMMA Investing LLC raised its stake in Genmab A/S by 194.0% during the 1st quarter. GAMMA Investing LLC now owns 1,135 shares of the company’s stock worth $34,000 after buying an additional 749 shares during the period. Allspring Global Investments Holdings LLC acquired a new position in shares of Genmab A/S during the first quarter worth approximately $43,000. Legacy Wealth Asset Management LLC lifted its holdings in shares of Genmab A/S by 4.6% in the 1st quarter. Legacy Wealth Asset Management LLC now owns 36,703 shares of the company’s stock worth $1,098,000 after purchasing an additional 1,611 shares in the last quarter. Janney Montgomery Scott LLC lifted its holdings in shares of Genmab A/S by 43.2% in the 1st quarter. Janney Montgomery Scott LLC now owns 17,369 shares of the company’s stock worth $520,000 after purchasing an additional 5,238 shares in the last quarter. Finally, Capstone Investment Advisors LLC acquired a new stake in Genmab A/S in the 1st quarter valued at $655,000. 7.07% of the stock is owned by institutional investors.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.